A blood IgA level of 318 mg/dL or higher independently predicted liver-related events even after the researchers accounted for advanced fibrosis — meaning the antibody carried prognostic information on its own.

Did the results hold up in other patients?

Yes. The researchers tested their findings in two additional groups.

In a separate cohort of 287 patients who had not undergone liver biopsy, those who developed liver-related events showed significantly higher blood IgA levels. And an independent multicenter cohort of 272 patients reproduced both the IgA-enriched subgroup and its link to liver-related events.

In the original cohort, the combination mattered most: patients with both elevated IgA and advanced fibrosis had that 48% ten-year cumulative incidence, compared with under 5% in everyone else.

"These findings show that MASLD is not a single, uniform disease and that high IgA may help identify a subgroup with a distinct pattern of disease progression," Kimura said. "The IgA-enriched phenotype provides another way to understand risk beyond fibrosis alone."

What links IgA to liver damage?

The team then investigated the biological mechanism. They examined liver tissue with several advanced methods: single-cell RNA sequencing (which measures gene activity in individual cells), spatial transcriptomics (which maps gene activity to specific locations in tissue) and immunohistochemistry (which uses antibodies to visualize specific molecules in tissue samples).

Several findings pointed to a gut–liver connection:

• In MASLD patients with advanced fibrosis, IgA-positive cells increased in the intestinal mucosa and submucosa — the inner lining and deeper layers of the gut wall
• Blood IgA levels correlated with EndoCAb IgG, a marker of intestinal barrier dysfunction, suggesting a leakier gut wall
• In liver tissue, spatial transcriptomics showed higher expression of the IGHA1 gene — the blueprint for part of the IgA antibody — in patients with advanced fibrosis
• Immunohistochemistry revealed more IgA-positive cells in portal regions, the areas around the portal veins where blood enters the liver
• Single-cell analysis showed B-lineage cells, including plasma cells, were the main producers of IGHA1

Genes active alongside IGHA1 were linked to B-cell signaling and extracellular matrix organization — the process by which the liver builds and rearranges its structural scaffolding. That pattern suggests a connection between immune activity and liver remodeling, the scarring process at the heart of fibrosis.

"By examining both the intestine and liver, we found evidence of coordinated IgA-associated immune activity along the gut–liver axis," Kimura said. "This provides a basis for further investigation of the biological features of the high-risk subgroup."

What are the limitations?

The findings are observational. The study identifies an association between IgA and disease progression, not proof that IgA causes liver damage. The cohorts were also largely Japanese, so the results may not transfer directly to other populations. The researchers themselves say prospective studies — ones that follow patients forward from diagnosis — and research in diverse populations will be needed before these findings can guide patient monitoring or treatment.

Why it matters

If confirmed, an IgA blood test could eventually give doctors a cheap and widely available tool to refine risk assessment in MASLD, layering immune information on top of fibrosis scoring. For now, the study's clearest contribution is conceptual: it shows that MASLD is not one uniform disease, and that the conversation between gut immune defenses and the liver plays a larger role in disease progression than fibrosis measurements alone can capture.